COMMITMENTS AND CONTINGENCIES - Narrative (Details) $ in Thousands				1 Months Ended			2 Months Ended	4 Months Ended	12 Months Ended
	Feb. 15, 2022 USD ($)	Jul. 08, 2021 claim	Dec. 03, 2020 plaintiff	Dec. 31, 2023 claim product operatingLease	Sep. 30, 2022 claim	Aug. 31, 2022 claim	Sep. 30, 2022 claim	Dec. 30, 2020 claim	Dec. 31, 2023 USD ($) product operatingLease claim	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2012 manufacturer
Operating Leased Assets [Line Items]
Number of operating leases | operatingLease				14					14
Operating lease, weighted average remaining lease term				3 years 10 months 24 days					3 years 10 months 24 days	2 years 7 months 6 days
Operating lease liability discount rates (in percent)				8.12%					8.12%	3.99%
Number of products marketed | product				3					3
Net Revenues									$ 486,816	$ 316,385	$ 216,136
Number of plaintiffs | plaintiff			6
Number of potential manufacturers | manufacturer												7
Number of complaints filed | claim		158		200	2	6	7	5
Azurity Pharmaceuticals
Operating Leased Assets [Line Items]
Settlement amount awarded to other party	$ 1,900
Royalties on future sales (as a percent)	20.00%
Novitium
Operating Leased Assets [Line Items]
Number of complaints filed | claim				28
Number of open complaints (more than) | claim				700					700
Unapproved Products
Operating Leased Assets [Line Items]
Net Revenues									$ 22,400	14,200	16,200
Unapproved Products | Contract Customer
Operating Leased Assets [Line Items]
Net Revenues									$ 1,900	$ 2,600	$ 2,400